Cannabis Rescheduling: What It Means for Operators and Investors—and How We’ll Help You Navigate It

The federal government’s anticipated move to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act is one of the most consequential policy shifts the industry has seen to date. While this change may promise tax relief, expanded research opportunities, and improved access to capital, it also likely introduces stricter federal oversight and new compliance challenges.

AAFCPAs’ Cannabis Practice has been preparing for this moment for years. We’ve tracked FDA/DEA movement and political rhetoric, analyzed the implications, and even advised the U.S. Treasury and Senate Finance Committee through the AICPA on critical 280E transition considerations. We continue to proactively help clients across the nation anticipate changes, seize opportunities, and mitigate risks.

Why Rescheduling Matters

• Elimination of IRS Code §280E: Cannabis businesses will finally be able to deduct ordinary expenses—payroll, rent, marketing—just like any other business. This will dramatically improve cash flow and profitability.
• Access to Capital: Rescheduling will likely reduce perceived risk for banks and investors, opening doors to better financing and M&A opportunities.
• Research and Innovation: Schedule III status may unlock pathways for clinical trials and FDA-approved cannabinoid medications.
• Compliance and Oversight: Expect FDA and DEA enforcement, pharma-grade standards, and tighter inventory controls.

What Rescheduling Does NOT Change

• Interstate Commerce Remains Prohibited: Even under Schedule III, cannabis cannot cross state lines until Congress authorizes it.
• Federal Legalization Is Still Pending: Rescheduling is a milestone, not full legalization.
• Banking Normalization Requires Legislative Action: SAFE Banking and other reforms remain critical.

For Investors

Rescheduling will likely increase valuations, boost M&A activity, and attract institutional capital. But it also may introduce new compliance costs and competitive pressures. Understanding these dynamics early is key to making informed investment decisions that position your portfolio for this new era.

Cannabis Rescheduling Insight from AAFCPAs

Rescheduling is a turning point, but not the finish line. The decisions you make now will shape your competitive position for years to come. AAFCPAs helps clients anticipate pharma-grade standards, strengthen inventory controls, and unlock research opportunities that position your business for innovation. We provide guidance on how to engage institutional partners, anticipate Big Pharma competition, and evaluate strategic consolidation while staying ahead of DEA rulemaking and avoiding costly enforcement risks.

Since 2012, AAFCPAs has been a trusted advisor to cannabis operators nationwide, delivering tax, audit, advisory, and outsourced accounting solutions. Our multi-disciplinary team—CPAs, consulting CFOs, tax attorneys, wealth advisors, and risk specialists—partners with businesses at every stage, from licensing to exit, and cultivation to retail. We optimize cash flow, manage multi-state tax obligations, and design strategies for growth, succession, or exit. In a post-280E world, we’re here to help you navigate complexity and seize opportunity.

These insights were contributed by David McManus, CPA, CGMA, Tax Partner & National Cannabis Practice Leader as well as Janice O’Reilly, CPA, CGMA and Ronald C. Lipof, Partners, Transaction Advisory & Cannabis Services.

Questions? Reach out to our authors directly or your AAFCPAs partner.

AAFCPAs offers a wealth of resources for the cannabis industry. Subscribe to get alerts and insights in your inbox.